BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that ten programs utilizing the company’s proprietary antibody-drug conjugate (ADC) technology are now in clinical development across its 11 current ADC collaborations. This includes two additional ADC programs for which Investigational New Drug applications were recently submitted to the U.S. Food and Drug Administration by Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), triggering milestone payments to Seattle Genetics. In addition to the 10 collaborator ADC programs, Seattle Genetics is conducting clinical trials of three other ADCs, including its lead program, brentuximab vedotin (SGN-35).
